{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T08:57:01Z","timestamp":1793350621066,"version":"4.5.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc. Diabetol. \u2013 Endocrinol. Rep."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are widely used for the management of type 2 diabetes and obesity, yet their long-term cardiovascular effects in high-risk populations continue to be actively evaluated. Given emerging evidence of both metabolic and direct cardiovascular actions, a comprehensive synthesis of cardiovascular outcome trial data is required to clarify the efficacy and safety of this drug class.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a systematic review and meta-analysis of randomised, placebo-controlled cardiovascular outcome trials evaluating GLP-1RAs in adults at high cardiovascular risk. Searches of PubMed, Embase (via OVID), and the Cochrane Library were performed for studies published between January 2015 and May 2025, in accordance with PRISMA 2020 guidelines. Eligible trials included\u2009\u2265\u20093,000 participants with a minimum follow-up of 12 months. The primary outcome was major adverse cardiovascular events (MACE). Secondary outcomes included cardiovascular mortality, all-cause mortality, non-fatal myocardial infarction, non-fatal stroke, hospitalisation for heart failure, and adverse events. Hazard ratios (HRs) with 95% confidence intervals (CIs) were pooled using random-effects meta-analysis. Risk of bias was assessed using the Cochrane RoB 2 tool, and certainty of evidence was evaluated using GRADE.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Eleven cardiovascular outcome trials comprising 91,490 participants were included, with a mean follow-up of 2.7 years. GLP-1RA treatment was associated with a significant reduction in MACE compared with placebo (HR 0.86, 95% CI 0.81\u20130.92). Meta-analysis also demonstrated significant reductions in cardiovascular mortality, all-cause mortality, non-fatal myocardial infarction, non-fatal stroke, and hospitalisation for heart failure. GLP-1RAs did not materially increase the risk of severe hypoglycaemia or acute pancreatitis, while gastrointestinal adverse effects were consistently more frequent.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>GLP-1 receptor agonists significantly reduce major cardiovascular events and mortality in high-risk populations, with a favourable long-term safety profile. These findings support the broader integration of GLP-1RAs into cardiovascular risk reduction strategies beyond glycaemic control.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical Abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1186\/s40842-026-00295-3","type":"journal-article","created":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T22:25:38Z","timestamp":1777587938000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The long-term cardiovascular safety and efficacy of glucagon-like peptide-1 (GLP-1) receptor agonists in high-risk cardiovascular populations: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"12","author":[{"given":"Kezia","family":"Peter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ocin","family":"Roka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Sepp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maya","family":"Warburton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jufen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon C.","family":"Cork","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,1]]},"reference":[{"key":"295_CR1","unstructured":"World Health Organization. Cardiovascular diseases. 2025. Available from: https:\/\/www.who.int\/health-topics\/cardiovascular-diseases#tab=tab_1. (Accessed 11 May 2025)."},{"key":"295_CR2","doi-asserted-by":"crossref","unstructured":"Yang H, Qinghua M, Han L, Liu H. A global prediction of cardiovascular disease from 2020 to 2030. Front Cardiovasc Med. 2025;12:1462705.","DOI":"10.3389\/fcvm.2025.1462705"},{"key":"295_CR3","unstructured":"National Institute for Health and Care Excellence. Cardiovascular disease: risk assessment and reduction, including lipid modification. London: National Institute for Health and Care Excellence; 2023. Available from: https:\/\/www.nice.org.uk\/guidance\/ng238. (Accessed 12 May 2025)."},{"key":"295_CR4","doi-asserted-by":"publisher","unstructured":"Ussher JR, Drucker DJ. Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action. Nat Rev Cardiol. 2023;20(7):463\u201374. Available from: https:\/\/doi.org\/10.1038\/s41569-023-00849-3. (Accessed 12 May 2025).","DOI":"10.1038\/s41569-023-00849-3"},{"key":"295_CR5","doi-asserted-by":"crossref","unstructured":"Alfaris N, Waldrop S, Johnson V, Boaventura B, Kendrick K, Stanford FC. GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review. EClinicalMedicine. 2024;75:102714.","DOI":"10.1016\/j.eclinm.2024.102782"},{"key":"295_CR6","doi-asserted-by":"publisher","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hr\u00f3bjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. https:\/\/doi.org\/10.1136\/bmj.n71.","DOI":"10.1136\/bmj.n71"},{"key":"295_CR7","unstructured":"Covidence. Covidence systematic review software. Melbourne (AU): Veritas Health Innovation; 2025. Available from: https:\/\/www.covidence.org\/. (Accessed: 19\/01\/2025)."},{"issue":"24","key":"295_CR8","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","volume":"389","author":"AM Lincoff","year":"2023","unstructured":"Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, Hardt-Lindberg S, Hovingh GK, Kahn SE, Kushner RF, Lingvay I, Oral TK, Michelsen MM, Plutzky J, Torn\u00f8e CW, Ryan DH. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New Engl J Med [e-journal]. 2023;389(24):2221\u201332. https:\/\/doi.org\/10.1056\/NEJMoa2307563.","journal-title":"New Engl J Med [e-journal]"},{"issue":"1","key":"295_CR9","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/s41591-021-01584-3","volume":"28","author":"CT Ruff","year":"2021","unstructured":"Ruff CT, Baron M, Im K, O\u2019Donoghue ML, Fiedorek FT, Sabatine MS. Subcutaneous infusion of exenatide and cardiovascular outcomes in type 2 diabetes: a non-inferiority randomized controlled trial. Nat Med [e-journal]. 2021;28(1):89\u201395. https:\/\/doi.org\/10.1038\/s41591-021-01584-3. https:\/\/pubmed.ncbi.nlm.nih.gov\/34873344\/.","journal-title":"Nat Med [e-journal]"},{"key":"295_CR10","doi-asserted-by":"crossref","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng H, Corbett MS, Eldridge SM, Emberson JR, Hern\u00e1n MA, Hopewell S, Hr\u00f3bjartsson A, Junqueira DR, J\u00fcni P, Kirkham JJ, Lasserson T, Li T, McAleenan A, Reeves BC, Shepperd S, Shrier I, Stewart LA, Tilling K, White IR, Whiting PF, Higgins JPT. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898. https:\/\/bmj.com\/content\/366\/bmj.l4898.full.","DOI":"10.1136\/bmj.l4898"},{"key":"295_CR11","unstructured":"Sch\u00fcnemann HJ, Bro\u017cek J, Guyatt GH, Oxman AD. GRADE handbook for grading quality of evidence and strength of recommendations. The GRADE Working Group; 2013. Available from: https:\/\/gdt.gradepro.org\/app\/handbook\/handbook.html. (Accessed:30\/04\/2025)."},{"key":"295_CR12","doi-asserted-by":"publisher","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JFE, Nauck MA, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016;375(4):311-22. https:\/\/doi.org\/10.1056\/NEJMoa1603827.","DOI":"10.1056\/NEJMoa1603827"},{"key":"295_CR13","doi-asserted-by":"publisher","unstructured":"Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, K\u00f8ber LV, Lawson FC, Ping L, Wei X, Lewis EF, Maggioni AP, McMurray JJV, Probstfield JL, Riddle MC, Solomon SD, Tardif J. Lixisenatide in participants with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015;373(23):2247\u20132257. https:\/\/doi.org\/10.1056\/NEJMoa1509225.","DOI":"10.1056\/NEJMoa1509225"},{"issue":"19","key":"295_CR14","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A, Eliaschewitz FG, J\u00f3dar E, Leiter LA, Lingvay I, Rosenstock J, Seufert J, Warren ML, Woo V, Hansen O, Holst AG, Pettersson J, Vilsb\u00f8ll T. Semaglutide and Cardiovascular Outcomes in Participants with Type 2 Diabetes. New Engl J Med [e-journal]. 2016;375(19):1834\u201344. https:\/\/doi.org\/10.1056\/NEJMoa1607141.","journal-title":"New Engl J Med [e-journal]"},{"issue":"9","key":"295_CR15","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1056\/NEJMoa1901118","volume":"381","author":"M Husain","year":"2019","unstructured":"Husain M, Birkenfeld AL, Donsmark M, Dungan K, Eliaschewitz FG, Franco DR, Jeppesen OK, Lingvay I, Mosenzon O, Pedersen SD, Tack CJ, Thomsen M, Vilsb\u00f8ll T, Warren ML, Bain SC. Oral semaglutide and cardiovascular outcomes in participants with Type 2 Diabetes. New Engl J Med [e-journal]. 2019;381(9):841\u201351. https:\/\/doi.org\/10.1056\/NEJMoa1901118.","journal-title":"New Engl J Med [e-journal]"},{"issue":"20","key":"295_CR16","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1056\/NEJMoa2501006","volume":"392","author":"DK McGuire","year":"2025","unstructured":"McGuire DK, Marx N, Mulvagh SL, Deanfield JE, Inzucchi SE, Pop-Busui R, Mann JFE, Emerson SS, Poulter NR, Engelmann MDM, Ripa MS, Hovingh GK, Brown-Frandsen K, Bain SC, Cavender MA, Gislum M, David J, Buse JB. Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes. New Engl J Med [e-journal]. 2025;392(20):2001\u201312. https:\/\/doi.org\/10.1056\/NEJMoa2501006.","journal-title":"New Engl J Med [e-journal]"},{"issue":"13","key":"295_CR17","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","volume":"377","author":"RR Holman","year":"2017","unstructured":"Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB, Chan JC, Choi J, Gustavson SM, Iqbal N, Maggioni AP, Marso SP, \u00d6hman P, Pagidipati NJ, Poulter N, Ramachandran A, Zinman B, Hernandez AF, EXSCEL Study Group. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. New Engl J Med [e-journal]. 2017;377(13):1228\u201339. https:\/\/doi.org\/10.1056\/NEJMoa1612917.","journal-title":"New Engl J Med [e-journal]"},{"key":"295_CR18","doi-asserted-by":"publisher","unstructured":"Thorpe KM, Patel C, Harrison R, Eapen Z, Ambrosy A, Coker R, Jenkins W, Anderson M, Migdalis I, Eliasson B, Chiang C, Cuadrado J, Santos NG, Litvak M, Loureyro J, Maldonado N, Gaal LV, Mihaylova-Shumkova R, Akhras R, Grondin F, Gupta M, Jones M, Lonn E, Lastuvka J, Cadinot D, Chevts J, Grosskopf J, Heymer P, Jung T, Luedemann J, Maxeiner S, Milek K, Regner S, Rieker W, Seufert J, Dimitriadis G, Pagkalos E, Mucsi J, Bonadonna R, Cosmo SE, Ponzani P, Trevisan R, Jang HC, Lee EY, Yu J, Vidrio-Vel\u00e1zquez M, Viergever EP, Guttormsen G, Wium C, Gadzinski W, Krzyzagorska E, Madej A, Romanczuk P, Garganeeva A, Kharakhulakh M, Lesnov V, Vasilevskaya O, Dawood S, Calonge AN, Charneco MQ, Rodr\u00edguez IR, Lundman P, S\u00f6derberg S, Chen JF, Sansanayudh N, Zlova T, Cookson T, Akhter F, Baum H, Aguiar RBD, Cheung D, Cohen A, Farris N, Forgosh L, Hartman I, Hermany P, Kulback S, Labroo A, Little R, Mehta A, Moran J, Rasouli N, Tan M, Wynne A, Yazdani S, Stewart M, Patel P, Sabol MB, Casson E, Hereghty B, Fernandez-Salazar E, Donaldson J, Jarosz M, Richards J, McLaughlin P, Breneman J, Shitut A, Bhosale A, Naicker P, Dumbre S. Albiglutide and cardiovascular outcomes in participants with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet. 2018;392:1519\u201329. https:\/\/doi.org\/10.1016\/s0140-6736(18)32261-x.","DOI":"10.1016\/s0140-6736(18)32261-x"},{"issue":"10193","key":"295_CR19","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","volume":"394","author":"HC Gerstein","year":"2019","unstructured":"Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, Probstfield J, Riesmeyer JS, Riddle MC, Ryd\u00e9n L, Xavier D, Atisso CM, Dyal L, Hall S, Rao-Melacini P, Wong G, Avezum A, Basile J, Chung N, Conget I, Cushman WC, Franek E, Hancu N, Hanefeld M, Holt S, Jansky P, Keltai M, Lanas F, Leiter LA, Lopez-Jaramillo P, Cardona Munoz EG, Pirags V, Pogosova N, Raubenheimer PJ, Shaw JE, Sheu WH, Temelkova-Kurktschiev T. REWIND Investigators. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394(10193):121\u201330. https:\/\/doi.org\/10.1016\/S0140-6736(19)31149-3. Epub 2019 Jun 9. PMID: 31189511.","journal-title":"Lancet"},{"issue":"10","key":"295_CR20","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1056\/NEJMoa2108269","volume":"385","author":"HC Gerstein","year":"2021","unstructured":"Gerstein HC, Sattar N, Rosenstock J, Ramasundarahettige C, Pratley R, Lopes RD, Lam CSP, Khurmi NS, Heenan L, Del Prato S, Dyal L, Branch K. Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes. New Engl J Med [e-journal]. 2021;385(10):896\u2013907. https:\/\/doi.org\/10.1056\/NEJMoa2108269.","journal-title":"New Engl J Med [e-journal]"},{"key":"295_CR21","doi-asserted-by":"publisher","first-page":"101641","DOI":"10.1016\/j.molmet.2022.101641","volume":"66","author":"BA McLean","year":"2022","unstructured":"McLean BA, Wong CK, Kabir MG, Drucker DJ. Glucagon-like Peptide-1 receptor Tie2\u2009+\u2009cells are essential for the cardioprotective actions of liraglutide in mice with experimental myocardial infarction. Mol metabolism. 2022;66:101641. https:\/\/doi.org\/10.1016\/j.molmet.2022.101641.","journal-title":"Mol metabolism"},{"key":"295_CR22","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1210\/en.2018-00004","volume":"159","author":"LL Baggio","year":"2018","unstructured":"Baggio LL, et al. GLP-1 Receptor Expression Within the Human Heart. Endocrinology. 2018;159:1570\u201384.","journal-title":"Endocrinology"},{"issue":"10","key":"295_CR23","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1016\/j.molmet.2015.07.008","volume":"4","author":"SC Cork","year":"2015","unstructured":"Cork SC, Richards JE, Holt MK, Gribble FM, Reimann F, Trapp S. Distribution and characterisation of Glucagon-like peptide-1 receptor expressing cells in the mouse brain. Mol metabolism. 2015;4(10):718\u201331. https:\/\/doi.org\/10.1016\/j.molmet.2015.07.008.","journal-title":"Mol metabolism"},{"issue":"11","key":"295_CR24","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1016\/j.molmet.2017.08.010","volume":"6","author":"LL Baggio","year":"2017","unstructured":"Baggio LL, Ussher JR, McLean BA, Cao X, Kabir MG, Mulvihill EE, Mighiu AS, Zhang H, Ludwig A, Seeley RJ, Heximer SP, Drucker DJ. The autonomic nervous system and cardiac GLP-1 receptors control heart rate in mice. Mol Metab. 2017;6(11):1339\u201349. Epub 2017 Sep 1. PMID: 29107282; PMCID: PMC5681270.","journal-title":"Mol Metab"},{"key":"295_CR25","doi-asserted-by":"publisher","first-page":"101024","DOI":"10.1016\/j.molmet.2020.101024","volume":"39","author":"MK Holt","year":"2020","unstructured":"Holt MK, Cook DR, Brierley DI, Richards JE, Reimann F, Gourine AV, Marina N, Trapp S. PPG neurons in the nucleus of the solitary tract modulate heart rate but do not mediate GLP-1 receptor agonist-induced tachycardia in mice. Mol metabolism. 2020;39:101024. https:\/\/doi.org\/10.1016\/j.molmet.2020.101024.","journal-title":"Mol metabolism"},{"key":"295_CR26","doi-asserted-by":"publisher","unstructured":"Gaspari T, Liu H, Welungoda I, Hu Y, Widdop RE, Knudsen LB, Simpson RW, Dear AE. A GLP-1 receptor agonist liraglutide inhibits endothelial cell dysfunction and vascular adhesion molecule expression in an ApoE-\/- mouse model. Diab Vasc Dis Res. 2011;8(2):117\u2013124. https:\/\/doi.org\/10.1177\/1479164111404257. Erratum in: Diab Vasc Dis Res. 2012;9(1):79. PMID: 21562063.","DOI":"10.1177\/1479164111404257"},{"key":"295_CR27","doi-asserted-by":"publisher","unstructured":"Nauck MA, Meier JJ. Management of endocrine disease: Are all GLP-1 agonists equal in the treatment of type 2 diabetes? Eur J Endocrinol. 2019;181(6):R211-R234. https:\/\/doi.org\/10.1530\/EJE-19-0566. PMID: 31600725.","DOI":"10.1530\/EJE-19-0566"},{"key":"295_CR28","doi-asserted-by":"publisher","unstructured":"Mousavi A, et al. Safety, efficacy, and cardiovascular benefits of combination therapy with SGLT-2 inhibitors and GLP-1 receptor agonists in patients with diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. Diabetol Metab Syndr. 2025;17(1):68. https:\/\/doi.org\/10.1186\/s13098-025-01635-6.","DOI":"10.1186\/s13098-025-01635-6"},{"key":"295_CR29","doi-asserted-by":"publisher","unstructured":"Wu JY, et al. A retrospective analysis of combination therapy with GLP-1 receptor agonists and SGLT2 inhibitors versus SGLT2 inhibitor monotherapy in patients with MASLD. Nat Commun. 2025;16(1):7459. https:\/\/doi.org\/10.1038\/s41467-025-62891-8.","DOI":"10.1038\/s41467-025-62891-8"}],"container-title":["Cardiovascular Diabetology \u2013 Endocrinology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40842-026-00295-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40842-026-00295-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40842-026-00295-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T22:25:40Z","timestamp":1777587940000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40842-026-00295-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,1]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["295"],"URL":"https:\/\/doi.org\/10.1186\/s40842-026-00295-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-8788582\/v1","asserted-by":"object"}]},"ISSN":["3059-4057"],"issn-type":[{"value":"3059-4057","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,1]]},"assertion":[{"value":"4 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All authors have read and approved the final version of the manuscript and consent to its publication in its current form.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"36"}}